Administrative Core

由HIV-1引起的获得性免疫缺陷综合症（艾滋病）是艾滋病患者死亡的主要原因。 非洲和全球第四大死因。IPCAVD正在开发艾滋病毒/艾滋病疫苗， 使用DNA进行初免，使用MVA进行加强（DNA/MVA疫苗），以及一种更简单、最终更容易 在这些疫苗的部署形式中，使用MVA进行初免和加强（MVA/MVA疫苗）。两者 DNA和MVA疫苗使用单个载体来表达病毒样颗粒（VLP）。这个IPCAVD寻求建立 GM-CSF，一种佐剂，导入这些产物中用于顺式表达。在临床前研究中， 大大加强了保护。IPCAVD的中心假设是GM-CSF改善了 通过增强粘膜存在的引发的T细胞和Ab应答来保护。进化枝C HIV-1， 在南部非洲和亚洲部分地区流行的占全世界感染的一半左右， >90%的病例发生在印度，印度是一个感染迅速蔓延的国家，其感染率已超过南非。 案件总数。该IPCAVD的疫苗开发工作集中在开发一个进化枝C 印度的疫苗 这一行政核心有五个具体目标： 为该计划提供全面协调 提供数据管理和统计支持 为知识产权申请和谈判提供后勤支持 协助出版物 保持预算和财政监督 博士项目主任哈里特罗宾逊将领导行政核心。她证明了 在领导IPCAVD项目和将概念从实验室转移到早期临床试验方面的经验 通过HVTN。

The acquired immunodeficiency syndrome (AIDS) caused by HIV-1 is the leading cause of death in Africa and the fourth leading cause of death worldwide. This IPCAVD is developing HIV/AIDS vaccines that use DNA for priming and MVA for boosting (DNA/MVA vaccine) as well as a simpler an ultimately easier to deploy form of these vaccines, the use of MVA for both priming and boosting (MVA/MVA vaccine). Both the DNA and MVA vaccines use single vectors to express virus like particles (VLP). This IPCAVD seeks to build GM-CSF, an adjuvant, into these products for expression in cis. In preclinical studies, co-expression of GMCSF has substantially enhanced protection. A central hypothesis for the IPCAVD is that GM-CSF improves protection by enhancing the mucosal presence of elicited T cell and Ab responses. Clade C HIV-1 which is endemic in southern Africa and parts of Asia accounts for about one half of the infections worldwide and >90% of the cases in India, a country with a rapidly spreading infection that has surpassed South Africa in its total number of cases. The vaccine development effort of this IPCAVD is focused on developing a clade C vaccine for India. This administrative core has five specific aims: ¿ Provide overall co-ordination for the Program ¿ Provide data management and statistical support ¿ Provide logistical support for intellectual property filings and negotiations ¿ Assist with publications ¿ Maintain budgets and fiscal oversight Dr. Harriet Robinson, the Program Director, will lead the Administrative core. She has demonstrated experience in leading IPCAVD programs and moving concepts from the bench to early phase clinical trials through the HVTN.